logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Knight Therapeutics Inc.

GUD.TO

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphomaā€¦ read more

Healthcare

Drug Manufacturersā€”Specialty & Generic

9 years

CAD

Exclusive to Premium users

Price

per share adjusted in CAD

$6.30

Price

+1.29%

$0.08

$6.22

Previous Close

$6.17

Open

Premium

52w Discount
Market Cap

$627.816m

Small

Price/Earnings

63x

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$372.776m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

$11.063m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

$0.11

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$795.437m

$1.003b

Assets

$207.605m

Liabilities

$53.919m

Debt
Debt to Assets

5.4%

0.8x

Debt to EBITDA
Free Cash Flow

-$15.175m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in CAD.
No items found.
ā†‘ TopSummaryPriceFinancials
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.